Janssen Pharmaceutica N.V.
Turnhoutseweg 30
Beerse
Antwerpen
2340
Tel: 32-14602226
87 articles with Janssen Pharmaceutica N.V.
-
Evotec Enters a Drug Discovery Collaboration with Janssen
6/14/2022
Evotec SE announced that the Company has entered a drug discovery collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
-
Alkermes Commences Arbitration Related to License Agreements with Janssen Pharmaceutica
4/19/2022
Alkermes plc (Nasdaq: ALKS) today announced that it commenced binding arbitration proceedings in respect of two license agreements with Janssen Pharmaceutica N.V. ("Janssen"), a subsidiary of Johnson & Johnson.
-
VantAI Announces Multi-Year Protein Degrader Discovery Collaboration with Janssen
4/13/2022
VantAI, an AI-first induced-proximity company, today announced it has entered into a multi-year collaboration agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (‘Janssen’).
-
Saladax Biomedical, Inc. Acquires Intellectual Property Portfolio for Antipsychotic Drug Tests
4/5/2022
Saladax Biomedical, Inc. is pleased to announce that it has acquired a patent portfolio for antipsychotic drug testing from Janssen Pharmaceutica NV.
-
Denali initiates dosing in Phase I/II frontotemporal dementia study. Intellia snags Orphan Drug Designation for experimental T cell receptor (TCR)-T cell therapy, NTLA-5001 in AML.
-
Midatech Pharma PLC Announces R&D Collaboration with Janssen on Second Molecule
3/9/2022
Midatech Pharma PLC, a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce an extension of its existing R&D collaboration with Janssen Pharmaceutica NV originally announced on 21 July 2020.
-
Remix Therapeutics Enters Collaboration with Janssen to Advance Small Molecule Therapeutics Using REMaster Drug Discovery Platform to Modulate RNA Processing
2/17/2022
Remix Therapeutics today announced a strategic collaboration with Janssen Pharmaceutica NV for the discovery and development of small molecule therapeutics that modulate RNA processing using Remix's REMaster drug discovery platform.
-
The strategic collaboration centers on Remix’s REMaster platform for the discovery and development of small molecule therapies that modulate RNA processing.
-
Midatech Pharma PLC Announces Extension of Janssen collaboration re Q-Sphera
1/17/2022
Midatech Pharma PLC is pleased to announce the extension of its R&D collaboration with Janssen Pharmaceutica NV originally announced on 21 July 2020.
-
TRexBio Announces Collaboration with Janssen to Discover Novel Targets for Immunology and Inflammation
1/6/2022
TRexBio Inc. today announced that it has entered into a multi-year research collaboration and licensing agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
-
SRI International Announces Collaboration Agreement with Janssen
1/5/2022
SRI International (SRI) today announced the company has entered into a collaboration agreement with Janssen Pharmaceutica NV (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
-
Alkermes Announces Receipt of Notices of Partial Termination From Janssen Pharmaceutica
11/8/2021
Alkermes plc announced that it received notices of partial termination in respect of two license agreements with Janssen Pharmaceutica N.V., a subsidiary of Johnson & Johnson and, under these agreements, a licensee and recipient of Alkermes' nanoparticulate formulation technology, known as NanoCrystal® technology.
-
Johnson & Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Trust for the Company's COVID-19 Vaccine Candidate
3/29/2021
Up to 400 million doses of the Company's single-shot vaccine candidate will be made available to African Union member states
-
Iktos Announces Research Collaboration with Janssen to Utilize Iktos’ Artificial Intelligence Technology to Increase Speed & Efficiency of Small Molecule Drug Discovery
4/29/2019
Iktos, a company specializing in Artificial Intelligence technologies applied to new drug design, announced the initiation of a collaboration agreement with Janssen Pharmaceutica NV.
-
Astex Pharmaceuticals Celebrates as Second New Cancer Drug Receives US Marketing Approval
4/12/2019
Astex Pharmaceuticals (Astex), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that it has received a milestone payment from Janssen Pharmaceutica N.V. (Janssen).
-
Astex Pharmaceuticals Celebrates as Second New Cancer Drug Receives US Marketing Approval
4/12/2019
Astex Pharmaceuticals (Astex), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that it has received a milestone payment from Janssen Pharmaceutica N.V. (Janssen).
-
Dr. Paul Janssen Award for Biomedical Research Issues 2019 Call for Nominations to Celebrate Champions of Science
1/10/2019
Nominations are now being accepted for the 2019 Dr. Paul Janssen Award for Biomedical Research.
-
Janssen Pharmaceutical Companies from Johnson & Johnson, confirmed topline data from its Phase III Antiretroviral Therapy as Long-Acting Suppression (ATLAS) trial of its two-drug combination for HIV.
-
Astex Continues to Deliver in Oncology as Erdafitinib, a Potential New Treatment for Metastatic Urothelial Cancer, Receives US FDA Breakthrough Therapy Designation
3/15/2018
Astex Pharmaceuticals (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that its pharmaceutical collaborator, Janssen Pharmaceutica N.V. (Janssen), has been granted Breakthrough Therapy Designation by the US FDA for erdafitinib in the treatment of metastatic urothelial cancer.
-
Janssen Pharmaceutica N.V. Announces Pivotal Phase III Study Results For Investigational Darunavir-Based Single-Tablet Regimen For The Treatment Of HIV-1 Infection In Adults Switching From Boosted Protease Inhibitors Plus Emtricitabine And Tenofovir Disop
10/9/2017